A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT05271604 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Cancer
Squamous Cell Carcinoma of Head and Neck
Recurrent Squamous Cell Carcinoma of the Head and Neck
Metastatic Cancer
Metastatic Squamous Cell Carcinoma of the Head and Neck

Interventions

BIOLOGICAL: Ozuriftamab Vedotin
BIOLOGICAL: Pembrolizumab
BIOLOGICAL: Evalstotug (BA3071)
BIOLOGICAL: Cetuximab

Sponsor

BioAtla, Inc.